Experts who advise the US Centers for Disease Control and Prevention on its hospital infection control guidelines have voted to recommend that health care providers wear masks during routine care for ...

The Centers for Disease Control and Prevention has published an infection prevention checklist for outpatient settings. The checklist, “Infection Prevention Checklist for Outpatient Settings: Minimum ...

Please provide your email address to receive an email when new articles are posted on . Symptoms of Candida auris can be nonspecific, making diagnosis a challenge. It is most common in long-term ...

Mount Sinai researchers have enhanced hospital screening protocols for Candida auris, an often-drug-resistant fungal pathogen the Centers for Disease Control and Prevention considers an urgent global ...

The Trump administration has terminated a federal advisory committee that issued guidance about preventing the spread of infections in health care facilities. The Healthcare Infection Control ...

There are limited data on the effectiveness of the vaccines against symptomatic coronavirus disease 2019 (Covid-19) currently authorized in the United States with respect to hospitalization, admission ...

The Trump administration shuttered the Healthcare Infection Control Practices Advisory Committee (HICPAC), ending three decades of medical advice used by the Centers for Disease Control and Prevention ...

This is a preview. Log in through your library . Abstract We screened 176 healthy, adult (aged 18—55 years) US refugees from tuberculosis (TB)-endemic countries to evaluate whether cytokine responses ...

Health officials are closely tracking spread of a fungus in health care settings that has been deemed an “urgent antimicrobial resistance threat.” Candida auris, also known as C. auris, is often ...

"We found that residents of these facilities suffered significantly greater morbidity and mortality from RSV infections compared with older adults living in the community." — Brenda L. Tesini, MD, ...

Preapproval trials showed that messenger RNA (mRNA)–based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety profile, yet these trials were subject to size ...